Dr Emadi discussed how the combination of venetoclax (Venclexta) plus pegcrisantaspase induced complete remissions in heavily pretreated patients with relapsed/refractory acute myeloid leukemia, including in those with prior exposure to venetoclax. He detailed data on the combination from a phase 1 study published in Blood, the significance of the findings, and more.